BioNTech

Biotechnology company from Germany

BNTX Nasdaq ISIN US09075V1026 SEC CIK 1776985 LEI 894500UZJ5LG1F8J1U58
Follow BioNTech Weekly email: filings, results

Financials

Reported figures only · latest: Q4 2025 EUR · IFRS
EPS, diluted -

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, IFRS
Revenue and net income10 fiscal years
  • Revenue
  • Net income
−€10B€0€10B€20BFY17FY19FY21FY23FY25
Show the numbers
YearRevenueNet income
FY25€2.9B−€1.1B
FY24€2.8B−€665.3M
FY23€3.8B€930.3M
FY22€17.3B€9.4B
FY21€19B€10.3B
FY20€482.3M€15.2M
FY19€108.6M−€179.1M
FY18€127.6M−€48M
FY17€61.6M−€85.7M
FY16--
MarginsShare of revenue
  • Gross margin
  • Operating margin
  • Net margin
−200%−100%0%100%FY17FY19FY21FY23FY25
Show the numbers
YearGross marginOperating marginNet margin
FY2577.6%−49%−39.6%
FY2480.3%−47.8%−24.2%
FY2384.3%18.1%24.4%
FY2282.7%73%54.5%
FY2184.7%80.5%54.2%
FY2087.7%−17.1%3.2%
FY1984%−167.1%−164.9%
FY1889.3%−42.2%−37.6%
FY1784.9%−99.5%−139.1%
FY16---
Free cash flowOperating cash flow minus capital expenditure
−€5B€0€5B€10B€15BFY17FY19FY21FY23FY25
Show the numbers
YearFree cash flow
FY25€280.9M
FY24−€78.8M
FY23€5.1B
FY22€13.2B
FY21€762.2M
FY20−€79.5M
FY19−€237.1M
FY18−€88.8M
FY17−€76.9M
FY16-
Returned to shareholdersDividends paid and shares bought back
€0€200M€400M€600MFY17FY19FY21FY23FY25
Show the numbers
YearDividends
FY25-
FY24€0
FY23€0
FY22€484.3M
FY21€0
FY20€0
FY19-
FY18-
FY17-
FY16-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • BioNTech
  • Healthcare median
−200%−100%0%100%FY17FY19FY21FY23FY25
Show the numbers
YearBioNTechHealthcare median
FY25−39.6%−30.6%
FY24−24.2%−47%
FY2324.4%−58%
FY2254.5%−80.4%
FY2154.2%−71.9%
FY203.2%−62.2%
FY19−164.9%−46.3%
FY18−37.6%−49.6%
FY17−139.1%−45.9%
FY16-−36%